Trial reportJournal of virology2002
Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.
Trial report in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00666107 (Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.Human vaccines & immunotherapeutics · 2018Trial
- Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.Journal of immunology (Baltimore, Md. : 1950) · 2009Trial
- Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.Clinical and vaccine immunology : CVI · 2007Trial
- Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study.International braz j urol : official journal of the Brazilian Society of UrologyTrial
- Role of prior HPV infection and CD4 T-cell count in modulating cellular immune responses to a three-dose nonavalent HPV vaccine schedule in PWH receiving ART.BMC medicine · 2025Article
- Therapeutic Role of HPV Vaccination on Benign HPV-induced Epithelial Proliferations in Immunocompetent and Immunocompromised Patients: Case Study and Review of the Literature.Open forum infectious diseases · 2024Review
- Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024Review
- Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts.Journal of clinical medicine · 2023Article
- Transplantation of Enterovirus 71 Virion Protein Particle Vaccine Protects Against Enterovirus 71 Infection in a Neonatal Mouse Model.Annals of transplantation · 2021Article
- Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.Molecular medicine reports · 2015Article
- Vaccine delivery using nanoparticles.Frontiers in cellular and infection microbiology · 2013Review
- Article
- Human papillomavirus disease and vaccines in adolescents.Adolescent medicine: state of the art reviews · 2010Review
- A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.Vaccine · 2010Article
- Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes.Virology journal · 2009Article
- Dermatologic manifestations of HPV in HIV-infected individuals.Current HIV/AIDS reports · 2009Review
- Management strategies and cost effectiveness in the prevention of cervical cancer.ClinicoEconomics and outcomes research : CEOR · 2009Article
- HPV Vaccines: today and in the Future.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2008Review
- Anaphylaxis following quadrivalent human papillomavirus vaccination.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
In this study, we evaluated the potency of a human papillomavirus (HPV) virus-like particle (VLP)-based vaccine at generating HPV type 11 (HPV-11)-specific cellular and humoral immune responses in seronegative women. The vaccine was administered by intramuscular immunizations at months 0, 2, and 6. A fourth immunization was administered to approximately half of the women at month 12. All vaccine recipients had positive HPV-11 VLP-specific lymphoproliferative responses at month 3 following the second immunization (geometric mean lymphoproliferative stimulation index [SI] = 28.4; 95% confidence interval [CI] = 16.9 to 48.0) and HPV-11 VLP-specific antibody titers following the first immunization at month 1 (geometric mean antibody titer = 53.9 milli-Merck units/ml, 95% CI, 34.8 to 83.7). In contrast, lymphoproliferative and antibody titer responses were never detected in the participants who received placebo. Relatively homogeneous lymphoproliferative responses were observed in all vaccinated women. The mean lymphoproliferative SI of the vaccinated group over the first 12 months of the study was 7.6-fold greater than that of the placebo group following the initial immunization. The cellular immune responses generated by VLP immunization were both Th1 and Th2, since peripheral blood mononuclear cells from vaccinees, but not placebo recipients, secreted interleukin 2 (IL-2), IL-5, and gamma interferon (IFN-gamma) in response to in vitro stimulation with HPV-11 VLP. The proliferation-based SI was moderately correlated with IFN-gamma production and significantly correlated with IL-2 production after the third immunization (P = 0.078 and 0.002, respectively). The robust lymphoproliferative responses were specific for HPV-11, since SIs generated against bovine papillomavirus and HPV-16 VLPs were not generally observed and when detected were similar pre- and postimmunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.